21688 results for «»
21688 results
Transcatheter tricuspid valve repair: will the current guidelines change our work in treating patients with relevant TR?
11 Dec 2025
Watch the replay to explore TTVR with P. Nikolai, H. Priebe-Brämer and M. Weber, and discuss current indications for transcatheter tricuspid interventions.
Holger Priebe-Brämer
Witten, Germany
From clinical benefits to cost effectiveness: impact of early intervention in asymptomatic severe AS
16 Nov 2025 – From PCR London Valves 2025
Francesco Saia discusses the clinical benefits of early intervention in asymptomatic severe aortic stenosis with Philippe Généreux and Tiffany Patterson. EARLY TAVR trial and supporting studies showed a reduction in death, stroke, and heart failure compared with surveillance. Economic modelling shows early intervention is cost-effective and...
ENCIRCLE 1-year outcomes: Shaping the future of MR treatment with the SAPIEN M3 system
18 Nov 2025 – From PCR London Valves 2025
Fabien Praz talks with Mayra Guerrero and Henryk Dreger about the ENCIRCLE trial on the Sapien M3 transcatheter mitral valve, which shows strong safety, durable MR reduction, and improved symptoms, quality of life, and LV remodelling. High-quality CT and echo are essential for #TMVR, which is...
Five-year outcomes following early experience with transapical TMVR
16 Nov 2025 – From PCR London Valves 2025
In this discussion, Christopher Allen and Michael Reardon review the five-year results of an early transapical TMVR system implanted in very high-risk, inoperable patients.
The device showed sustained elimination of mitral regurgitation, with over 80% of patients maintaining trace or no MR at five years and no...
One-year results from the ADALA trial
16 Nov 2025 – From PCR London Valves 2025
Left atrial appendage (LAA) closure is a new focus at this year’s PCR London Valves Course, and, in this interview, Xavier Freixa and Christopher Allen discuss the ADALA trial and its impact on post-occlusion management.
The study compared three months of low-dose DOAC with three months of...
Beyond TAVI
16 Nov 2025 – From PCR London Valves 2025
This session offers a glimpse into cutting-edge structural heart interventions beyond TAVI. It introduces novel devices in early development stages targeting aortic valve stenosis and leaflet modification, discusses strategies to facilitate or defer TAVI, and provides opportunities for engagement with early-stage start-up partners innovating in structural...
Is iatrogenic atrial septum defect closure a necessary procedure?
17 Nov 2025 – From PCR London Valves 2025
Philipp Lurz and Saibal Kar discuss iatrogenic atrial septal defects from transseptal procedures. Small ones usually close on their own, while large defects causing significant shunting need closure to prevent right heart overload. Some moderate defects may be beneficial by decompressing the left atrium, so closure...
PARTNER 3 — 7-year follow-up: what it means for low-risk patients
16 Nov 2025 – From PCR London Valves 2025
Philippe Généreux and Philippe Pibarot discuss the long-term findings from PARTNER 3 and their practical implications for patient care.
They review the 7-year comparison of transfemoral TAVR versus surgical aortic-valve replacement in symptomatic patients with severe aortic stenosis who are at low surgical risk, and why the...
Should we consider TTVR in patients with straightforward anatomy who are eligible for T-TEER?
17 Nov 2025 – From PCR London Valves 2025
Lukas Stolz and Rebecca Hahn discuss advances in transcatheter tricuspid valve intervention, emphasising that reducing tricuspid regurgitation (TR) to mild levels is key for improving patient outcomes, including mortality and heart failure hospitalisations. Decision-making between transcatheter edge-to-edge repair (T-TEER) and transcatheter tricuspid valve replacement (TTVR) depends...
TARGET study interim results: safety and performance of Cardiovalve replacement system for tricuspid regurgitation
16 Nov 2025 – From PCR London Valves 2025
Georg Nickenig and Christopher Allen discuss transcatheter replacement for the tricuspid valve and a dedicated transfemoral device in this interview, focusing on the TARGET study.
TARGET set out to answer two questions: can tricuspid regurgitation (TR) be reduced to mild or zero, and what are the safety...
Featured research: latest advances in mitral TEER and valve repair technologies
16 Nov 2025 – From PCR London Valves 2025
This session presents featured research on mitral valve interventions, including two-year outcomes from the MitraClip G4 EXPAND study, comparative data of mitral TEER versus redo surgery in failed surgical repair, evidence from novel TEER programs in non-surgical centers, and safety and efficacy results of the NeoNova...
Challenging mitral valve-in-valve
16 Nov 2025 – From PCR London Valves 2025
Gain insights into challenging mitral valve-in-valve procedures addressing small cavity anatomy, alignment difficulties, combined LAMPOON and leak closure techniques, and high-risk TMVR cases with complex left ventricular outflow tract obstruction and ECMO support.
TAVI and coronary artery disease
16 Nov 2025 – From PCR London Valves 2025
This session focuses on the interplay between TAVI and coronary artery disease, discussing high-risk TAVR cases requiring complex left main PCI with prophylactic ECMO support. It provides guidance on timing and strategies for managing concomitant coronary artery disease in TAVI patients, addressing the critical decision-making process...
New tricuspid valve devices
16 Nov 2025 – From PCR London Valves 2025
Examine new tricuspid valve devices and innovative procedural approaches, featuring cases of challenging anatomy with pacemaker lead repositioning, use of LuX-valve plus in massive regurgitation, position optimization in transjugular TTVR, and early clinical experiences from feasibility studies.
TAVI: vascular complications
16 Nov 2025 – From PCR London Valves 2025
This session examines vascular complications associated with transfemoral TAVI procedures, featuring challenging cases such as initial procedural obstacles, complex post-TAVI vascular events, and unusual complications. It also explores advanced techniques like intravascular lithotripsy to optimize TAVI outcomes in patients with severe calcific iliofemoral disease.
New approaches in aortic regurgitation
16 Nov 2025 – From PCR London Valves 2025
Explore new diagnostic and therapeutic approaches for managing aortic regurgitation. This session covers imaging modalities, guideline-directed patient selection, current transcatheter treatment techniques, and emerging TAVI technologies designed specifically for non-calcific aortic valve pathology.
Hotline - TAVI - Part 1
16 Nov 2025 – From PCR London Valves 2025
This comprehensive session examines the latest evidence and clinical trial data on TAVI, including comparisons of balloon-expandable versus self-expanding valves in failed bioprostheses, techniques to reduce coronary obstruction risk, and real-world outcomes across diverse populations. Cost-effectiveness analyses and longitudinal studies further inform best practices for optimizing...
Valve interventions in congenital heart disease
16 Nov 2025 – From PCR London Valves 2025
This session presents complex valve interventions in congenital heart disease, highlighting challenging cases such as positional hypoxaemia due to iatrogenic atrial defects, navigating residual shunts after PFO closure, and transcatheter pulmonary valve replacement in native right ventricular outflow tracts without pre-stenting. It also examines an intriguing...
Procedural imaging for tricuspid valve interventions
16 Nov 2025 – From PCR London Valves 2025
Master procedural imaging techniques essential for tricuspid valve interventions, including TOE views, multi-phase reconstruction, and 3D/4D steering. This session also covers quantification of residual tricuspid regurgitation post-device deployment and the appropriate use of intracardiac echocardiography.
